Mechanism of action of 0.1% Tacrolimus ointment in combination with phototherapy in treatment of vitiligo

To survey the mechanism of action of 0.1% Tacrolimus ointment in combination with phototherapy during repigmentation process through histological study in adults with vitiligo

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20181117041686N1

Enrollment

Registered

2019-01-04

Start date

2018-12-06

Completion date

Unknown

Last updated

2019-01-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

vitiligo. Vitiligo

Interventions

Intervention 1: Intervention group: Whole-body Nb-UVB phototherapy will be performed using a cabin equipped with TL 01 lamps (Waldmann Medizintechnik, Villingen-Schwenningen, Germany) with wavelengths

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: patients with symmetrical, unstable and non-segmental vitiligo

Exclusion criteria

Exclusion criteria: receiving any topical or systemic treatments during the last 3 months pregnancy, lactation history of any hypersensitivity to tacrolimus history of premalignant or malignant skin lesions photosensitivity, photo-mediated disorders, taking photo-sensitizing drugs concomitant radiotherapy, chemotherapy, or immunosuppressive therapy segmental or mucosal vitiligo

Design outcomes

Primary

Measure	Time frame
Melanocyte stem cells location. Timepoint: before intervention and 2 months after intervention. Method of measurement: staining of the skin samples using monoclonal antibodies for the melanocytes and assessing the slides under a microscope.	—

Secondary

Measure	Time frame
The percentage of skin repigmentation. Timepoint: Before intervention and 2 months after intervention. Method of measurement: Using a quartile grading scale (grade 0, no repigmentation; grade 1, 1%-24%; grade 2, 25%-49%; grade 3, 50%-74%; grade 4, 75%-99%; grade 5, complete resolution).	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMina Almasi-Nasrabadi

Skin Research Center of Shahid Beheshti University of Medical Sciences

mina.almasi2@gmail.com+98 21 2274 1507

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026